vs
Side-by-side financial comparison of CS Disco, Inc. (LAW) and Strata Critical Medical, Inc. (SRTA). Click either name above to swap in a different company.
CS Disco, Inc. is the larger business by last-quarter revenue ($41.9M vs $22.7M, roughly 1.8× Strata Critical Medical, Inc.). On growth, Strata Critical Medical, Inc. posted the faster year-over-year revenue change (361.2% vs 14.3%). Over the past eight quarters, CS Disco, Inc.'s revenue compounded faster (7.9% CAGR vs -33.6%).
CS Disco, Inc. is a leading legal technology provider that develops cloud-based software solutions for legal practitioners. Its core offerings include e-discovery, document review, case management, and legal workflow automation tools, serving law firms, corporate legal teams, and government legal departments primarily in North America.
Strata Critical Medical, Inc. is a medical technology firm designing, producing and distributing disposable medical products for critical care, anesthesia and surgical use cases. It serves healthcare providers across North America and some European markets, focusing on improving patient safety and clinical efficiency.
LAW vs SRTA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $41.9M | $22.7M |
| Net Profit | $-9.6M | — |
| Gross Margin | 74.2% | -0.9% |
| Operating Margin | 1.7% | -18.4% |
| Net Margin | -23.0% | — |
| Revenue YoY | 14.3% | 361.2% |
| Net Profit YoY | 15.6% | — |
| EPS (diluted) | $-0.15 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $41.9M | — | ||
| Q4 25 | $41.2M | $22.7M | ||
| Q3 25 | $40.9M | $49.3M | ||
| Q2 25 | $38.1M | $70.8M | ||
| Q1 25 | $36.7M | $54.3M | ||
| Q4 24 | $37.0M | $-8.7M | ||
| Q3 24 | $36.3M | $36.1M | ||
| Q2 24 | $36.0M | $67.9M |
| Q1 26 | $-9.6M | — | ||
| Q4 25 | $-8.5M | — | ||
| Q3 25 | $-13.7M | $57.4M | ||
| Q2 25 | $-10.8M | $-3.7M | ||
| Q1 25 | $-11.4M | $-3.5M | ||
| Q4 24 | $-25.2M | — | ||
| Q3 24 | $-9.2M | $-2.0M | ||
| Q2 24 | $-10.8M | $-11.3M |
| Q1 26 | 74.2% | — | ||
| Q4 25 | 75.1% | -0.9% | ||
| Q3 25 | 75.5% | 23.6% | ||
| Q2 25 | 74.6% | 25.1% | ||
| Q1 25 | 74.1% | 22.1% | ||
| Q4 24 | 74.2% | — | ||
| Q3 24 | 73.1% | 20.8% | ||
| Q2 24 | 74.2% | 24.1% |
| Q1 26 | 1.7% | — | ||
| Q4 25 | -22.4% | -18.4% | ||
| Q3 25 | -35.3% | -11.4% | ||
| Q2 25 | -31.0% | -7.0% | ||
| Q1 25 | -34.4% | -14.0% | ||
| Q4 24 | -70.6% | — | ||
| Q3 24 | -30.0% | -19.7% | ||
| Q2 24 | -34.4% | -17.9% |
| Q1 26 | -23.0% | — | ||
| Q4 25 | -20.7% | — | ||
| Q3 25 | -33.4% | 116.5% | ||
| Q2 25 | -28.4% | -5.3% | ||
| Q1 25 | -31.1% | -6.4% | ||
| Q4 24 | -68.1% | — | ||
| Q3 24 | -25.3% | -5.4% | ||
| Q2 24 | -30.1% | -16.7% |
| Q1 26 | $-0.15 | — | ||
| Q4 25 | $-0.13 | $-0.11 | ||
| Q3 25 | $-0.22 | $0.70 | ||
| Q2 25 | $-0.18 | $-0.05 | ||
| Q1 25 | $-0.19 | $-0.04 | ||
| Q4 24 | $-0.43 | $-0.11 | ||
| Q3 24 | $-0.15 | $-0.03 | ||
| Q2 24 | $-0.18 | $-0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $103.0M | $31.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $123.9M | $279.1M |
| Total Assets | $162.4M | $325.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $103.0M | — | ||
| Q4 25 | $114.6M | $31.0M | ||
| Q3 25 | $113.5M | $22.8M | ||
| Q2 25 | $114.5M | $58.8M | ||
| Q1 25 | $118.8M | $34.8M | ||
| Q4 24 | $129.1M | $18.4M | ||
| Q3 24 | $126.8M | $20.0M | ||
| Q2 24 | $130.0M | $26.3M |
| Q1 26 | $123.9M | — | ||
| Q4 25 | $128.1M | $279.1M | ||
| Q3 25 | $130.6M | $283.0M | ||
| Q2 25 | $137.9M | $223.1M | ||
| Q1 25 | $142.2M | $219.7M | ||
| Q4 24 | $147.5M | $221.9M | ||
| Q3 24 | $167.3M | $233.5M | ||
| Q2 24 | $170.9M | $229.4M |
| Q1 26 | $162.4M | — | ||
| Q4 25 | $173.6M | $325.5M | ||
| Q3 25 | $174.8M | $335.1M | ||
| Q2 25 | $164.9M | $257.9M | ||
| Q1 25 | $168.0M | $250.6M | ||
| Q4 24 | $180.3M | $256.7M | ||
| Q3 24 | $194.4M | $282.9M | ||
| Q2 24 | $198.0M | $280.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.7M | $-8.3M |
| Free Cash FlowOCF − Capex | — | $-10.2M |
| FCF MarginFCF / Revenue | — | -44.7% |
| Capex IntensityCapex / Revenue | — | 8.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-58.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $-11.7M | — | ||
| Q4 25 | $762.0K | $-8.3M | ||
| Q3 25 | $-979.0K | $-37.3M | ||
| Q2 25 | $-4.2M | $-3.1M | ||
| Q1 25 | $-10.5M | $-246.0K | ||
| Q4 24 | $2.1M | $-1.8M | ||
| Q3 24 | $-2.9M | $6.4M | ||
| Q2 24 | $-650.0K | $8.4M |
| Q1 26 | — | — | ||
| Q4 25 | $255.0K | $-10.2M | ||
| Q3 25 | $-2.0M | $-40.1M | ||
| Q2 25 | $-5.2M | $-5.4M | ||
| Q1 25 | $-11.0M | $-2.9M | ||
| Q4 24 | $1.5M | $-6.3M | ||
| Q3 24 | $-3.7M | $-3.0M | ||
| Q2 24 | $-1.3M | $-7.7M |
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | -44.7% | ||
| Q3 25 | -5.0% | -81.4% | ||
| Q2 25 | -13.6% | -7.6% | ||
| Q1 25 | -30.1% | -5.3% | ||
| Q4 24 | 4.1% | 72.7% | ||
| Q3 24 | -10.3% | -8.2% | ||
| Q2 24 | -3.6% | -11.4% |
| Q1 26 | — | — | ||
| Q4 25 | 1.2% | 8.1% | ||
| Q3 25 | 2.6% | 5.7% | ||
| Q2 25 | 2.5% | 3.2% | ||
| Q1 25 | 1.4% | 4.8% | ||
| Q4 24 | 1.5% | -52.6% | ||
| Q3 24 | 2.4% | 25.8% | ||
| Q2 24 | 1.8% | 23.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LAW
Segment breakdown not available.
SRTA
| Other Clinical | $11.4M | 50% |
| Transplant Clinical | $9.0M | 39% |
| Other | $2.4M | 11% |
